- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2018
- Public Summary Document (PSD) March 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2018 PBAC Meeting - Word
Sofosbuvir with velpatasvir and voxilaprevir – March 2018
Sofosbuvir with velpatasvir and voxilaprevir: 400mg/100mg/100mg tablets; VOSEVI®
Last updated
26 October 2018